An integrated pan-cancer analysis of leucine-rich repeat containing protein 59: a potential biomarker for prognostic and immunotherapy

Leucine-rich repeat containing protein 59 (LRRC59), a ribosome binding protein located on the endoplasmic reticulum and the nuclear envelope. Although it has been found in blood plasma and linked to the development of a few cancers, the function of LRRC59 is still largely unknown and there is no systematic investigation on its role in various human cancers. We performed a multi-omics data analysis to investigate the expression of LRRC59 in human tumors and its correlation with clinical prognosis, gene set enrichment, mutation status, and immune infiltration in cancers using the TCGA, GTEx, GEPIA2, HPA, UALCAN, Timer2, GTBAdb, cBioPortal database and R packages. In the majority of TCGA tumors, LRRC59 was expressed significantly differently (up-regulated in 25 and down-regulated in 4 cancer types). High LRRC59 expression has been linked to worse prognosis in several malignancies. In numerous carcinomas, the expression of LRRC59 was associated clinicopathological stages. The LRRC59 regulation network was mainly involved in the pathways related to endoplasmic reticulum homeostatic and cell proliferation. In addition, the expression of LRRC59 is also strongly associated with the immune cell infiltration. LRRC59 could also predicts the response to immunotherapy. LRRC59 is a potential valuable biomarker not only for diagnostic and prognostic, but also for immunotherapy in most cancers.